These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23667128)

  • 21. HPV vaccination: the promise & problems.
    Sankaranarayanan R
    Indian J Med Res; 2009 Sep; 130(3):322-6. PubMed ID: 19901441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human papillomavirus quadrivalent vaccine: a look behind the numbers.
    Flaherty DK; Alkhateeb FM
    Ann Pharmacother; 2009 Apr; 43(4):740-4. PubMed ID: 19276314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global HPV vaccination.
    Arie S
    BMJ; 2011 Feb; 342():d1042. PubMed ID: 21325382
    [No Abstract]   [Full Text] [Related]  

  • 24. Cervical cancer: the second-generation vaccines move forward.
    Tuma RS
    J Natl Cancer Inst; 2009 Jun; 101(11):774-5. PubMed ID: 19470948
    [No Abstract]   [Full Text] [Related]  

  • 25. Human papillomavirus vaccine: now for boys too?
    Jenson HB; Baltimore RS
    Curr Opin Pediatr; 2011 Feb; 23(1):78-84. PubMed ID: 21157346
    [No Abstract]   [Full Text] [Related]  

  • 26. [Dream vaccine or still a dream?].
    Haug C
    Tidsskr Nor Laegeforen; 2007 May; 127(10):1331. PubMed ID: 17519980
    [No Abstract]   [Full Text] [Related]  

  • 27. Human papillomavirus.
    Brody H
    Nature; 2012 Aug; 488(7413):S1. PubMed ID: 22932432
    [No Abstract]   [Full Text] [Related]  

  • 28. [HIV therapy: tenofir DF is available in 68 developing countries at production costs price].
    Med Klin (Munich); 2003 Jul; 98(7):XV-XVI. PubMed ID: 12945544
    [No Abstract]   [Full Text] [Related]  

  • 29. Mathematical model of HPV provides insight into impacts of risk factors and vaccine.
    Kim JJ
    PLoS Med; 2006 May; 3(5):e164. PubMed ID: 16573363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HPV & HPV vaccination: issues in developing countries.
    Bharadwaj M; Hussain S; Nasare V; Das BC
    Indian J Med Res; 2009 Sep; 130(3):327-33. PubMed ID: 19901442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
    Goldie SJ; O'Shea M; Diaz M; Kim SY
    Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Getting to know human papillomavirus (HPV) and the HPV vaccines.
    Smith GD; Travis L
    J Am Osteopath Assoc; 2011 Mar; 111(3 Suppl 2):S29-34. PubMed ID: 21415377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adolescents' access and consent to the human papillomavirus vaccine: a critical aspect for immunization success.
    Farrell RM; Rome ES
    Pediatrics; 2007 Aug; 120(2):434-7. PubMed ID: 17671069
    [No Abstract]   [Full Text] [Related]  

  • 34. Introduction of human papillomavirus (HPV) vaccination in Sweden.
    Tegnell A; Dillner J; Andrae B
    Euro Surveill; 2009 Feb; 14(6):. PubMed ID: 19215721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.
    Sinanovic E; Moodley J; Barone MA; Mall S; Cleary S; Harries J
    Vaccine; 2009 Oct; 27(44):6196-202. PubMed ID: 19698807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HPV vaccine mandates: just say 'no' to the "great big public health experiment".
    Onder RF
    Mo Med; 2008; 105(1):8-11. PubMed ID: 18300597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy.
    La Torre G; de Waure C; Chiaradia G; Mannocci A; Capri S; Ricciardi W
    Vaccine; 2010 Apr; 28(19):3379-84. PubMed ID: 20197141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine.
    Kane MA
    Gynecol Oncol; 2010 May; 117(2 Suppl):S32-5. PubMed ID: 20129654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
    Westra TA; Daemen T; Postma MJ; Wilschut JC
    Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.
    Thomas TL
    Pediatr Nurs; 2008; 34(5):429-31. PubMed ID: 19051848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.